Previous Close | 9.24 |
Open | 9.22 |
Bid | 8.87 x 1000 |
Ask | 8.89 x 1200 |
Day's Range | 8.58 - 9.35 |
52 Week Range | 4.98 - 65.33 |
Volume | |
Avg. Volume | 2,160,056 |
Market Cap | 1.32B |
Beta (5Y Monthly) | 1.21 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.08 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for BBIO
– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be both a best-in-class therapy and the first oral therapy for PH1 and recurrent kidney stone formers – Based on the tolerability and potency of the oral therapy, BridgeBio has met with regulators and intends to initiate a Phase 2/3 pivotal study by the end of 2022 – At the end of 2022, BridgeBio also intends to lau
BridgeBio Pharma Inc (NASDAQ: BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve cells (neurons) in the brain to send and receive messages. Data from the first two participants show rapid and robust post-treatment decreases in N-acetylaspartate (NAA) in urine and, significantly, in cerebrospinal fluid (C
- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease - Initial pharmacodynamic results for two participants show unprecedented decreases in N-acetylaspartate (NAA) in the brain and urine, suggesting the therapy is producing functional ASPA enzyme - If successful, BridgeBio’s gene therapy could be the first therapeutic option for children born with Canavan disease, a devastating and fatal neurodev